Limit this search to....

Therapeutic Treatment for Benign Prostatic Hyperplasia
Contributor(s): Kirby, Roger S. (Editor), McConnell, John D. (Editor), Fitzpatrick, John (Editor)
ISBN: 1841846015     ISBN-13: 9781841846019
Publisher: CRC Press
OUR PRICE:   $209.00  
Product Type: Hardcover - Other Formats
Published: June 2005
Qty:
Temporarily out of stock - Will ship within 2 to 5 weeks
Annotation: The spectrum of treatment options for benign prostatic hyperplasia is matched by the spectrum of disease severity. New medications and minimally invasive modalities offer a greater range of choices to both the urologist and the patient. As BPH is rarely life-threatening, management is generally focussed on quality of life. With up to 90% of men in their 80s suffering from BPH to some extent, the prevalence of the disease is growing. It is imperative that patients be offered the full options available to manage BPH. Pharmacologic therapies available for the treatment of lower urinary tract symptoms secondary to BPH include alpha-adrenoceptor antagonists, such as terazosin, doxazosin, alfuzosin and tamsulosin, and the 5-alpha-reductase inhibitors, finasteride and dutasteride. Other strategies, such as plant-derived medication or watchful waiting, are applied to varying extents. This well-written and highly illustrated guide covers all these therapies and will well serve all urologists treating BPH.
Additional Information
BISAC Categories:
- Medical | Urology
Dewey: 616.65
Physical Information: 0.64" H x 7.57" W x 10" (1.68 lbs) 210 pages
 
Descriptions, Reviews, Etc.
Publisher Description:

The spectrum of available treatment options for benign prostatic hyperplasia (BPH) is matched by the spectrum of disease severity, and with up to 90% of men in their 80s suffering from BPH to some extent, it is imperative that patients are offered the full range of options to manage the disease.

Pharmacologic therapies available for the treatment of lower urinary tract symptoms secondary to BPH include alpha-adrenoceptor antagonists, such as terazosin, doxazosin, alfuzosin and tamsulosin, and the 5-alpha-reductase inhibitors, finasteride and dutasteride. Other strategies, such as plant-derived medication or watchful waiting, are applied to varying extents.

Derived from the benchmark title on BPH - Textbook of Benign Prostatic Hyperplasia - this well written and highly illustrated guide covers all these therapies and presents physicians with all they need to know to successfully manage the disease.